%0 Journal Article %T Tratamiento de la leucemia promieloc¨ªtica con ¨¢cido transretinoico y quimioterapia intensiva: Evoluci¨®n cl¨ªnica y molecular %A Hern¨¢ndez Ram¨ªrez %A Porfirio %A Mart¨ªnez Antu£¿a %A Gisela %A Espinosa Mart¨ªnez %A Edgardo %A Losada Buchill¨®n %A Rafael %A Gonz¨¢lez Otero %A Alejandro %A Mach¨ªn Garc¨ªa %A Sergio %A Dortic¨®s Balea %A Elvira %A Milan¨¦s Rold¨¢n %A Mar¨ªa Teresa %A Cayado %A Niubis %A Gramatges Ortiz %A Anissa %A Bravo Regueiro %A Jenny %A Carnot Ur¨ªa %A Jos¨¦ %J Revista Cubana de Hematolog£¿-a, Inmunolog£¿-a y Hemoterapia %D 2002 %I Editorial Ciencias M¨¦dicas %X forty nine patients diagnosed with promyelocytic leukemia were treated with retinoic acid (45-50 mg/m2/day) during induction; afterwards, a consolidation therapy was applied with daunorubicin and arabinosylcitosine, followed by a maintenance therapy with 6 mercaptopurine and methotrexate for 2 years and a half. an evolving clinical, hematological and molecular study was performed. forty three patients achieved complete remission (88%); 9 (47%) of 19 patients and 18(90%) of 20 patients had reached molecular remission after induction and consolidation respectively. global survival rate at 5 years was 65%¡À8% and event-free survival rate was 63%¡À7%. disease-free survival rate was 71%¡À 7% in the same period %K leukemia promyelocytic %K acute [drug therapy] %K tretinoin %K daunorubicin %K cytarabine %K drug therapy combination %K evolution %K molecular. %U http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0864-02892002000200002&lng=en&nrm=iso&tlng=en